BioCryst Pharmaceuticals BCRX Finance Lease Liability Payment Due
Finance Lease Liability Payment Due at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseLiabilityPaymentsDue.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's finance lease liability payment due.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's finance lease liability payment due?
- BioCryst Pharmaceuticals (BCRX) reported finance lease liability payment due of $2.67M in Q1 2026.
- How has BioCryst Pharmaceuticals's finance lease liability payment due changed year-over-year?
- BioCryst Pharmaceuticals's finance lease liability payment due decreased by 42.5% year-over-year, from $4.65M to $2.67M.
- What does finance lease liability payment due mean?
- This represents the total future cash payments required to satisfy finance lease obligations. Unlike operating leases, finance leases are treated similarly to debt-financed asset acquisitions. This metric is crucial for understanding the company's total debt-like obligations and capital structure.